| scholarly article | Q13442814 |
| P819 | ADS bibcode | 2007PNAS..104.6864G |
| P356 | DOI | 10.1073/PNAS.0701451104 |
| P932 | PMC publication ID | 1871876 |
| P698 | PubMed publication ID | 17428917 |
| P5875 | ResearchGate publication ID | 6399398 |
| P50 | author | Hilary Koprowski | Q936389 |
| P2093 | author name string | Yuri Gleba | |
| Stuart N Isaacs | |||
| Yuhong Xiao | |||
| Vyacheslav Andrianov | |||
| Sergei Spitsin | |||
| Maxim Golovkin | |||
| Robert Brodzik | |||
| Yuriy Smirnov | |||
| Karen Markley | |||
| Natalia Pogrebnyak | |||
| P2860 | cites work | Smallpox DNA vaccine protects nonhuman primates against lethal monkeypox | Q24623839 |
| Turning plants into protein factories | Q28267867 | ||
| Design of safe and biologically contained transgenic plants: tools and technologies for controlled transgene flow and expression | Q30319947 | ||
| Systemic Agrobacterium tumefaciens-mediated transfection of viral replicons for efficient transient expression in plants | Q30320231 | ||
| Magnifection--a new platform for expressing recombinant vaccines in plants | Q30320267 | ||
| In planta engineering of viral RNA replicons: efficient assembly by recombination of DNA modules delivered by Agrobacterium | Q30320503 | ||
| A protein-based smallpox vaccine protects mice from vaccinia and ectromelia virus challenges when given as a prime and single boost | Q30445071 | ||
| Biopharmaceuticals derived from genetically modified plants | Q33208097 | ||
| The looming threat of bioterrorism | Q33536420 | ||
| Epitope-mapping studies define two major neutralization sites on the vaccinia virus extracellular enveloped virus glycoprotein B5R. | Q33780553 | ||
| Severe acute respiratory syndrome (SARS) S protein production in plants: development of recombinant vaccine | Q33863306 | ||
| Design and production of recombinant subunit vaccines. | Q34043255 | ||
| Protection conferred by recombinant Yersinia pestis antigens produced by a rapid and highly scalable plant expression system | Q34250117 | ||
| The envelope G3L protein is essential for entry of vaccinia virus into host cells | Q35024119 | ||
| Smallpox vaccination: a review, part I. Background, vaccination technique, normal vaccination and revaccination, and expected normal reactions | Q35175726 | ||
| Analysis of Agrobacterium tumefaciens virulence mutants in leaf discs | Q35600056 | ||
| A calmodulin-binding protein from Arabidopsis has an essential role in pollen germination | Q35918766 | ||
| Vaccines and sera through plant biotechnology | Q36055951 | ||
| Reemergence of monkeypox: prevalence, diagnostics, and countermeasures | Q36313212 | ||
| Plant-derived pharmaceuticals--the road forward | Q36313817 | ||
| Deletion of the vaccinia virus B5R gene encoding a 42-kilodalton membrane glycoprotein inhibits extracellular virus envelope formation and dissemination. | Q36651113 | ||
| Characterization of a vaccinia virus-encoded 42-kilodalton class I membrane glycoprotein component of the extracellular virus envelope | Q36687208 | ||
| Protective immunity to vaccinia virus induced by vaccination with multiple recombinant outer membrane proteins of intracellular and extracellular virions | Q37511609 | ||
| Subunit recombinant vaccine protects against monkeypox | Q40300878 | ||
| Antibody neutralization of the extracellular enveloped form of vaccinia virus | Q40829727 | ||
| Neutralizing and protective antibodies directed against vaccinia virus envelope antigens | Q40976393 | ||
| A constitutively expressed vaccinia gene encodes a 42-kDa glycoprotein related to complement control factors that forms part of the extracellular virus envelope | Q42610963 | ||
| The vaccinia virus 42-kDa envelope protein is required for the envelopment and egress of extracellular virus and for virus virulence | Q42622915 | ||
| Expression of immunogenic VP2 protein of infectious bursal disease virus in Arabidopsis thaliana | Q43169181 | ||
| The detection of monkeypox in humans in the Western Hemisphere. | Q43217764 | ||
| Multiple diagnostic techniques identify previously vaccinated individuals with protective immunity against monkeypox. | Q43219070 | ||
| Immunization of mice with recombinant gp41 in a systemic prime/mucosal boost protocol induces HIV-1-specific serum IgG and secretory IgA antibodies | Q43654259 | ||
| Antibodies against the extracellular enveloped virus B5R protein are mainly responsible for the EEV neutralizing capacity of vaccinia immune globulin | Q43767401 | ||
| The promoter-terminator of chrysanthemum rbcS1 directs very high expression levels in plants | Q43940828 | ||
| Vaccine manufacturing: challenges and solutions | Q44862237 | ||
| Overexpression of human erythropoietin (EPO) affects plant morphologies: retarded vegetative growth in tobacco and male sterility in tobacco and Arabidopsis | Q45239759 | ||
| Immunization with a single extracellular enveloped virus protein produced in bacteria provides partial protection from a lethal orthopoxvirus infection in a natural host | Q45422947 | ||
| Four-gene-combination DNA vaccine protects mice against a lethal vaccinia virus challenge and elicits appropriate antibody responses in nonhuman primates | Q45728877 | ||
| DNA vaccination with vaccinia virus L1R and A33R genes protects mice against a lethal poxvirus challenge | Q45745063 | ||
| Immunization without needles | Q46308392 | ||
| Biodefense. Smallpox vaccines: looking beyond the next generation | Q47636452 | ||
| Differential induction of mucosal and systemic antibody responses in women after nasal, rectal, or vaginal immunization: influence of the menstrual cycle | Q74335025 | ||
| Constitutive expression of the beta-ketothiolase gene in transgenic plants. A major obstacle for obtaining polyhydroxybutyrate-producing plants | Q77932531 | ||
| Mucosal immunization using recombinant plant-based oral vaccines | Q82345610 | ||
| P433 | issue | 16 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | smallpox | Q12214 |
| P304 | page(s) | 6864-6869 | |
| P577 | publication date | 2007-04-11 | |
| P1433 | published in | Proceedings of the National Academy of Sciences of the United States of America | Q1146531 |
| P1476 | title | Smallpox subunit vaccine produced in Planta confers protection in mice | |
| P478 | volume | 104 |
| Q33936717 | Antibody against Extracellular Vaccinia Virus (EV) Protects Mice through Complement and Fc Receptors |
| Q37349246 | Comparative evaluation of the immune responses and protection engendered by LC16m8 and Dryvax smallpox vaccines in a mouse model |
| Q45370650 | Efficient and stable expression of GFP through Wheat streak mosaic virus-based vectors in cereal hosts using a range of cleavage sites: formation of dense fluorescent aggregates for sensitive virus tracking |
| Q35194874 | Emerging antibody products and Nicotiana manufacturing |
| Q27027725 | Expression of recombinant vaccines and antibodies in plants |
| Q47738620 | Generation of plant-derived recombinant DTP subunit vaccine |
| Q81790871 | Immunogenic properties of plant-derived recombinant smallpox vaccine candidate pB5 |
| Q83222891 | Immunological assessment of plant-derived avian flu H5/HA1 variants |
| Q36020905 | Influenza virus-like particles coated onto microneedles can elicit stimulatory effects on Langerhans cells in human skin. |
| Q37461110 | Molecular smallpox vaccine delivered by alphavirus replicons elicits protective immunity in mice and non-human primates |
| Q33681834 | Norovirus Narita 104 virus-like particles expressed in Nicotiana benthamiana induce serum and mucosal immune responses |
| Q41837568 | Optimization and utilization of Agrobacterium-mediated transient protein production in Nicotiana |
| Q30317744 | Plant Viral Vectors for Delivery by Agrobacterium |
| Q37776713 | Plant-made immunogens and effective delivery strategies |
| Q37616370 | Plant-made vaccine antigens and biopharmaceuticals |
| Q26783107 | Plant-produced candidate countermeasures against emerging and reemerging infections and bioterror agents |
| Q37438883 | Plants as bioreactors for the production of vaccine antigens. |
| Q34018403 | Plants as bioreactors: Recent developments and emerging opportunities |
| Q28384852 | Principles of antidote pharmacology: an update on prophylaxis, post‐exposure treatment recommendations and research initiatives for biological agents |
| Q37290098 | Recent progress in the development of plant derived vaccines |
| Q98189279 | Short-term and longer-term protective immune responses generated by subunit vaccination with smallpox A33, B5, L1 or A27 proteins adjuvanted with aluminum hydroxide and CpG in mice challenged with vaccinia virus |
| Q37393765 | Smallpox vaccines for biodefense |
| Q34288498 | The identification of HLA class II-restricted T cell epitopes to vaccinia virus membrane proteins |
| Q37644601 | Tobacco, a highly efficient green bioreactor for production of therapeutic proteins |
| Q37776717 | Transient expression systems for plant-derived biopharmaceuticals |
| Q37106374 | Viral vectors for production of recombinant proteins in plants |
Search more.